In a phase 1 trial, a single intratumoral injection of oncolytic virus SVV-001 with ipilimumab and nivolumab was safe in high ...

Halfdan Sorbye, MD, PhD, discusses why accurately distinguishing NET G3 from NEC is critical, as the wrong first-line therapy ...

Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.

Erik S. Mittra, MD, PhD, highlighted how new PRRT trials may reshape neuroendocrine tumor care, from retreatment and ...

In DAREON-7, first-line obrixtamig plus chemo yielded responses across DLL3 expression levels in epNEC, with the most durable ...

The Community Oncology Alliance said CMS’s final 2027 outpatient rule pays 340B hospitals ASP minus 28% for drugs, but ...

In the CABINET trial, cabozantinib extended PFS vs placebo in advanced NETs regardless of hormone functional status, with ...

In patients with advanced SSTR2-positive NETs who had not received PRRT, [²¹²Pb]VMT-α-NET produced objective response rates ...

PRRT retreatment achieved high disease control in NETs, and longer benefit from first PRRT was tied to longer ...

Jennifer R. Eads, MD, discussed radioligand therapy in younger and older patients with NETs, highlighting safety data and ...

Toni Choueiri, MD, discusses KEYNOTE-564 subgroup findings, adjuvant pembrolizumab after nephrectomy, overtreatment risks, and emerging biomarkers in renal cell carcinoma.

The FDA has granted accelerated approval to amivantamab and hyaluronidase for advanced HNSCC based on the OrigAMI-4 trial.